Share-based Payment Arrangement, Expense in USD of ROCKET PHARMACEUTICALS, INC. from 2014 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Rocket Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2014 to Q3 2025.
  • Rocket Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $9.76M, a 13.2% decline year-over-year.
  • Rocket Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $42M, a 1.7% decline year-over-year.
  • Rocket Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $43.9M, a 11.5% increase from 2023.
  • Rocket Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $39.4M, a 27.1% increase from 2022.
  • Rocket Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $31M, a 6.06% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

ROCKET PHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $42M $9.76M -$1.49M -13.2% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-06
Q2 2025 $43.5M $10.9M -$475K -4.19% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-07
Q1 2025 $44M $10.3M +$79K +0.77% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q4 2024 $43.9M $11.1M +$1.16M +11.7% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-27
Q3 2024 $42.8M $11.2M +$932K +9.04% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-06
Q2 2024 $41.8M $11.3M +$1.09M +10.6% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-07
Q1 2024 $40.7M $10.3M +$1.34M +15% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q4 2023 $39.4M $9.93M +$237K +2.45% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-27
Q3 2023 $39.2M $10.3M +$2.64M +34.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $36.5M $10.2M +$2.88M +39% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $33.7M $8.92M +$2.65M +42.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $31M $9.69M +$2.66M +37.7% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-27
Q3 2022 $28.4M $7.68M +$688K +9.84% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $27.7M $7.37M +$58K +0.79% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $27.6M $6.27M -$1.63M -20.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-05
Q4 2021 $29.2M $7.04M +$967K +15.9% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 $28.3M $6.99M +$2.94M +72.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-04
Q2 2021 $25.3M $7.31M +$2.82M +62.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $22.5M $7.9M +$3.94M +99.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $18.6M $6.07M +$2.71M +80.7% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $15.9M $4.05M +$1.35M +50.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 $14.5M $4.49M +$351K +8.48% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $14.2M $3.96M +$781K +24.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $13.4M $3.36M +$537K +19% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $12.8M $2.69M +$82K +3.14% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $12.8M $4.14M +$1.35M +48.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $11.4M $3.18M -$2.2M -40.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 $13.6M $2.82M +$2.46M +684% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 $11.1M $2.61M +$1.91M +273% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 $9.23M $2.79M +$2.63M +1641% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $6.6M $5.38M +$5.28M +5336% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $1.32M $360K +$2.06M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-08
Q3 2017 -$744K $701K -$105K -13% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$639K $160K -$526K -76.7% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 -$113K $99K -$387K -79.6% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-11
Q4 2016 $274K -$1.7M Oct 1, 2016 Dec 31, 2016 10-K 2019-03-08
Q3 2016 $806K +$432K +116% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 $686K +$492K +254% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 $486K -$464K -48.8% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q3 2015 $374K Jul 1, 2015 Sep 30, 2015 10-Q 2015-11-12
Q2 2015 $194K Apr 1, 2015 Jun 30, 2015 10-Q 2015-08-07
Q1 2015 $950K Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-11

ROCKET PHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $43.9M +$4.51M +11.5% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-27
2023 $39.4M +$8.4M +27.1% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-27
2022 $31M +$1.77M +6.06% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-27
2021 $29.2M +$10.7M +57.5% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 $18.6M +$5.2M +38.9% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 $13.4M -$230K -1.69% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $13.6M +$12.3M +930% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-01
2017 $1.32M +$1.05M +382% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-08
2016 $274K Jan 1, 2016 Dec 31, 2016 10-K 2019-03-08
2014 $7.00* Jan 1, 2014 Dec 31, 2014 10-K 2016-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.